Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

3.320
+0.0100.30%
Volume:82.32M
Turnover:272.59M
Market Cap:62.32B
PE:24.59
High:3.370
Open:3.340
Low:3.280
Close:3.310
Loading ...

BUZZ-Sino Biopharmaceutical rises most in nearly 5 weeks on LaNova deal

Reuters
·
20 Nov 2024

BRIEF-Sino Biopharmaceutical Signs Equity Investment And Strategic Cooperation Agreement

Reuters
·
20 Nov 2024

Sino Biopharmaceutical - Signing Equity Investment and Strategic Cooperation Agreement With Lanova Medicines

THOMSON REUTERS
·
20 Nov 2024

Sino Biopharmaceutical - Deal for Lm-108 in Mainland China Region

THOMSON REUTERS
·
20 Nov 2024

Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod

MT Newswires Live
·
15 Nov 2024

BRIEF-Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"

Reuters
·
14 Nov 2024

Sino Biopharmaceutical - Approval Granted for Clinical Trials of Egfr Inhibitor "Tqb3002" in US

THOMSON REUTERS
·
14 Nov 2024

The five-year shareholder returns and company earnings persist lower as Sino Biopharmaceutical (HKG:1177) stock falls a further 4.0% in past week

Simply Wall St.
·
12 Nov 2024

Sino Biopharmaceutical Cancer Drug Gets Marketing Approval in China

MT Newswires Live
·
11 Nov 2024

BRIEF-Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa

Reuters
·
11 Nov 2024

Sino Biopharmaceutical - Approval for Marketing of Kras G12c Inhibitor Garsorasib Tablet From Nmpa

THOMSON REUTERS
·
11 Nov 2024

Greater China Stocks Rise; Shanghai Sees Largest Increase

Dow Jones
·
04 Nov 2024

BRIEF-Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech

Reuters
·
31 Oct 2024

BRIEF-Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln

Reuters
·
30 Oct 2024

Sino Biopharmaceutical - Qtrly Profit Attributable RMB1.15 Bln

THOMSON REUTERS
·
30 Oct 2024

Sino Biopharmaceutical - Beijing Runkang Agreed to Acquire 29.99% Stake in Hob Biotech Group

THOMSON REUTERS
·
30 Oct 2024